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Polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) are closely related conditions of unknown
etiology. Both are characterized by older age at onset, being more common in women, evidence of
systemic inﬂammation, and generally responding well to corticosteroids. Controversy remains as to
whether they are two different conditions or two ends of the spectrum of a single disease. Few pop-
ulation-based studies have evaluated the epidemiology of PMR because of lack of a universally accepted
diagnostic and classiﬁcation criteria. PMR and GCA are one of the commonest reasons for long-term
corticosteroid therapy in older age. Newer therapies for these conditions have been evaluated, including
conventional antirheumatic disease-modifying drugs as well as newer biologics. Vascular risk factors
should be modiﬁed as patients with GCA suffer an increased number of cerebrovascular events. PMR and
GCA cause signiﬁcant morbidity and mortality, so it is important for general practitioners and geriatri-
cians to recognize them early. There is increased recognition of a need for long-term follow-up for aortic
aneurysm development and large vessel involvement.
Copyright  2010, Asia Paciﬁc League of Clinical Gerontology & Geriatrics. Published by Elsevier Taiwan
Open access under CC BY-NC-ND license.LLC.1. Polymyalgia rheumatica
Polymyalgia rheumatica (PMR) is an inﬂammatory condition of
unknown etiology mainly affecting people older than 50 years. It is
a clinical syndrome characterized by
 Aching and stiffness in the neck, shoulders and pelvic girdles,
 Systemic symptoms,
 A raised erythrocyte sedimentation rate (ESR).
It usually responds rapidly to lowdoses of corticosteroid and has
a favorable prognosis.1
2. Giant cell arteritis
Giant cell arteritis (GCA) is a vasculitis of large- andmedium-sized
vessels mostly affecting individuals older than 50 years. Early
recognition and treatment is vital to prevent blindness and other
systemic complications because of occlusion and rupture of involved
arteries.r the Elderly, Addenbrooke’s
undation Trust, Hills Road,
s.uk (D.R. Forsyth).
linical Gerontology & Geriatrics. P3. Clinical features
PMRmostly presents with a subacute or chronic onset of aching
and morning stiffness in the neck, shoulders, and pelvic girdles.
Symptoms are usually bilateral and symmetric but asymmetric
pain can occur.2 Constitutional symptoms of malaise, tiredness,
depression, anorexia, weight loss, and fever are common. In most
cases, symptoms have been present for weeks or months before the
diagnosis is established. Stiffness is usually the predominant
feature; it is particularly severe ﬁrst thing in the morning and after
inactivity during the day. Inﬂammatory synovitis and joint effu-
sions have been described.3 Synovitis of the knees, wrists, and
sternoclavicular joints is most common, and its involvement is
transient and mild. Presence of persistent synovitis particularly
with radiological changes of juxtra-articular osteoporosis or
erosions should raise the possibility of inﬂammatory arthritis.
Physical examination may reveal decreased range of active move-
ment of the shoulders, cervical spine, and hips.
GCA can cause a wide range of symptoms, but most patients
have clinical features related to affected arteries. Common features
include headache and scalp tenderness particularly in the temporal
and occipital region. Scalp tenderness is common around the
temporal and occipital arteries; on palpation, the vessels are often
thickened and have reduced or no pulsation.
Visual disturbance is described in 25%e50% of patients with
GCA, ocular lesions are caused by occlusion of the various orbital orublished by Elsevier Taiwan LLC. Open access under CC BY-NC-ND license.
Table 2
American College of Rheumatology criteria for diagnosing GCA8
Criterion Deﬁnition
1. Age at onset
more than 50 yr
Development of symptoms or ﬁndings beginning
aged 50 yr or older
2. New headache New onset of, or new type of, localized pains
in the head
3. Temporal artery
abnormality
Temporal artery tenderness to palpation or
decreased pulsation, unrelated to atherosclerosis
of cervical arteries
4. Increased ESR ESR more than 50 mm/hr by Westergren method
5. Abnormal artery
biopsy
Biopsy specimen with artery showing vasculitis
characterized by a predominance of mononuclear
cell
GCA¼ giant cell arteritis; ESR¼ erythrocyte sedimentation rate; PMR¼ polymyalgia
rheumatica.
Table 3
The British Society for Rheumatology and British Health Professionals in Rheuma-
tology stepped approach to diagnosing PMR10
Steps in diagnosis and
management
Deﬁnition
1. Inclusion criteria Bilateral shoulder girdle and/or
pelvic pain
Morning stiffness for more than 45 min
Abrupt onset
Age more than 50 yr
Duration more than 2 wk
Acute-phase response (raised CRP/ESR)
2. Exclusion criteria Active cancer
Infection
Active GCA
Inﬂammatory (RA and other
arthropathies, SLE, myopathies,
other CTDs)
Noninﬂammatory (local shoulder
and hip conditions, ﬁbromyalgia,
other pain syndromes)
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relative afferent papillary defect), and fundoscopy {pale swollen
optic disc with hemorrhages of anterior ischemic optic neuropathy
[AION]} is therefore essential. The most common ocular lesion is
AION, which usually leads to complete visual loss; arteritis is
responsible for 12% of AION.5 Features suggesting arteritic AION
included systemic symptoms, early elevated ESR, amaurosis fugax,
and early visual loss.5 Visual loss is the most serious feature; it is
sudden, painless, and mostly irreversible. Presence of visual
symptoms is a medical emergency as prompt recognition of the
condition and treatment can prevent blindness.
Other symptoms of GCA include pain on chewing because of
claudication of jaw muscle. Less common features include hemi-
paresis, peripheral neuropathy, deafness, depression, and confu-
sion. Involvement of coronary arteries may lead to myocardial
infarction. Noncranial arteries can also become involved. Large
vessel involvement, including thoracic aorta, is less likely the
higher the ESR (hazard ratio of 0.80 per 10 mm/hr ESR above the
norm).6
4. Classiﬁcation and diagnostic criteria
As both conditions present with wide range of systemic features
and there is no single diagnostic test, a combination of ﬁndings is
needed for their diagnosis. For PMR, there are a number of different
criteria sets with no international consensus. That proposed by Bird
et al.7 is useful in clinical practice (Table 1). A diagnosis of PMR
requires three of the seven listed features; the presence of just
three features conﬁrms a sensitivity of 92% and a speciﬁcity of 80%.7
The American College of Rheumatology has established criteria for
the classiﬁcation of GCA (Table 2). These criteria ensure consistency
of diagnosis and allow comparison of patient groups between
different centers; however, failure to fulﬁll these criteria need not
preclude a diagnosis of either PMR or GCA in an individual patient.9
The British Society for Rheumatology (BSR) and British Health
Professionals in Rheumatology (BHPR) have recently published
consensus guidelines on the management of PMR10 and GCA.11
Evaluating each condition in turn, these guidelines not only give
advice on how best to secure a ﬁrm diagnosis and when to refer to
specialists but also detailed advise on the longer term monitoring
of disease activity and complications. The guidelines seek to
simplify an approach to diagnosis and initial management of PMR
(Table 3) and GCA (Table 4), supported as much as possible by an
admittedly limited evidence base.12
5. Relationship between PMR and GCA
PMR and GCA are considered as closely related conditions repre-
senting a spectrum of disease. These two conditions may occur
independently or in the same individual, either together or separated
by time. Individuals with temporal artery biopsy (TAB)-proven GCA
have been described to develop features of PMR and vice versa.1Table 1
Bird et al.7 diagnostic criteria for PMR
Combination of any three criteria necessary for diagnosis
 Age more than 65 yr
 ESR more than 40 mm/hr
 Bilateral shoulder pain and/or stiffness
 Morning stiffness for more than 1 hr
 Onset of illness within two wk
 Depression and/or weight loss
 Bilateral upper arm tenderness
PMR¼ polymyalgia rheumatica.Systemic involvement is similar in both PMR and GCA. It is difﬁcult
to maintain a practical distinction between them by clinical or
histological criteria; however, no deﬁnitive conclusion can be drawn
about the nature of this association.13
6. Epidemiology
Few population-based studies have evaluated the epidemiology
of PMR because of lack of universally accepted diagnostic and clas-
siﬁcation criteria. PMR and GCA almost exclusively affect older adults
and are rarely diagnosed under the age of 50 years. The estimated
prevalence of PMR, in the United States, is 1 in 133 people over the
age of 50 years.14 The incidence of PMR and GCA increases with age,
with a peak in those 70e80 years of age. The prevalence of PMR
approaches that of rheumatoid arthritis in older age, approximately3. Trial of low dose steroid Prednisolone 15e20 mg daily
Clinical response in less than
1 wk (at least 70% global improvement)
Lab resolution in 3e4 wk
4. Follow-up (4e6) wk No alternative diagnosis found
from thorough screen at time or
presentation (include myeloma screen,
autoimmune screen,
TSH, CK, LFTS, calcium)
5. Diagnosis PMR likely Gradual steroid tapering
Consider bone protection
PMR¼ polymyalgia rheumatica; CRP¼ C-reactive protein; ESR¼ erythrocyte sedi-
mentation rate; GCA¼ giant cell arteritis; RA¼ rheumatoid arthritis; SLE¼ systemic
lupus erythematosus; CTD¼ connective tissue diseases; TSH¼ thyroid stimulating
hormone; CK¼ creatine kinase; LFTS¼ liver function tests.
Table 4
The British Society for Rheumatology and British Health Professionals in Rheuma-
tology criteria for diagnosing GCA11
Steps in diagnosis and management Deﬁnition
1. Suspect diagnosis of GCA Apply ACR criteria as Table 2
2. Immediate initiation
of steroid therapy
Uncomplicated (no jaw/visual
symptoms)dprednisolone
40 mg daily
Complicated (jaw/visual
symptoms)dprednisolone
60 mg daily, but consider i.v.
methylprednisolone
500 mge1 g daily if evolving
visual symptoms
Aspirin 75 mg daily for
both groups
3. Urgent referral
to specialists
For specialist opinion
For TAB biopsy
Opthalmic assessment is
suspected AION
4. Biopsy positive Gradual steroid tapering
Consider methotrexate
Bone protection
Monitor for large vessel
involvement or relapses
5. Biopsy negative Specialist reviewdif clinical
suspicion or US suggests
GCA or AION treat as GCA
If low clinical suspicion rapid
steroid taper within 2 wk and seek
alternative diagnosis
GCA¼ giant cell arteritis; ACR¼American College of Rheumatology;
i.v.¼ intravenous; TAB¼ temporal artery biopsy; AION¼ anterior ischemic optic
neuropathy; US¼ ultrasound.
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in all age groups. The incidence of GCA increases with latitude in the
northern hemisphere, with at least a twofold increase in incidence in
Scandinavian countries compared with Northwestern Spain.16 A
study of biopsy-proven GCA demonstrated an average annual inci-
dence and prevalence of 17 and 223, respectively per 100,000 pop-
ulation aged 50 years or more.17
The characteristics of both PMR and GAC appear broadly similar
in mainland China as in the Western hemisphere: 75% aged more
than 65 years at diagnosis, 95% have bilateral upper arm stiffness,
and 100% have a raised ESR.18 However, generalized joint stiffness
may be less common and time to diagnosis signiﬁcantly longer in
mainland China.18,19 Interestingly, one small Chinese cohort found
a mean age at disease onset of 43.13 years (range 28e60).19 Both
PMR and GCA appear to be less common entities in China than in
the Western hemisphere.20
A Japanese national survey gave prevalence for GCA, in patients
aged 50 years and older, of 1.47 per 100,000 population, a 100-fold
less than the prevalence quoted in a western population.21
Studies in transplanted ethnic populations in United States have
also found a lower than expected rate of GCA,22 it is possible that
this may change as these populations continue to age.23
7. Etiology and pathogenesis
At present, the underlying pathologic abnormality in PMR is
unclear. An increasing incidence of GCA and PMR after the age of 50
years implies a relationship with aging. Aging of the immune and
neuroendocrine systems may be important factors in the late onset
of GCA. The higher incidence rates in Occidentals, for example, in
Scandinavia, Northern Europe, or United States, and lower rates in
Orientals, for example, China and Japan, support a possible genetic
determinant.A distinct prodromal event resembling inﬂuenza or viral pneu-
monia is often noted by patients. However, viral studies have
generally produced negative results. No association has been
demonstrated with viruses that induce multinucleated giant cells,
such as measles, herpes simplex, Epstein-Barr, and respiratory
syncytial viruses.24,25 GCA is limited to vessels with an internal
elastic lamina, and electron microscopy shows fragmentation of
this with mononuclear cell accumulation compatible with cell-
mediated injury. Several studies using polymerase chain reaction to
detect the presence of Chlamydia pneumoniae, parvovirus B19, and
several of the human herpes viruses in TAB specimens have yielded
negative results.26,27 Some still hypothesize the existence of a trig-
gering antigen of unknown nature activating T-cells in the artery
wall, following an immune response to infection.28 Evidence in
favor of this is a dual peak in cases of PMR and GCA in association
with seasonal variation in Danish respiratory infections (speciﬁ-
cally Mycoplasma pneumoniae, Parvovirus B19, and Chlamydia
pneumoniae).29
A primary immunological basis for both PMR and GCA has been
investigated. Circulating concentrations of interleukin-6 are
increased,with normal concentrations of TNF-a both inpatientswith
an arteritic presentation of GCA and in those presenting with PMR. A
selective depletion of circulating CD8 T lymphocytes in patients with
GCA has been observed in most studies. No increase in expression of
human leukocyte antigen-DR has been found on circulatory CD4.30
8. Investigations
The characteristic laboratory abnormality seen in most patients
with GCA and PMR is a high ESR; it can exceed 100 mm/hr in GCA.
Less striking elevation or even normal values may occasionally be
seen.31 However, an ESR of less than 30 mm/hr is associated with
a likelihood ratio of GCA of only 0.02.32 The ESR also provides
a useful means of monitoring response to the treatment; however,
it must be appreciated that some elevation of the ESR may occur in
otherwise apparently healthy older people. A normal ESR is
occasionally found with active biopsy-proven GCA.33 Other acute
phase changes may also be present, such as increase in C-reactive
protein, ﬁbrinogen, and decrease in serum albumin concentra-
tion.34 Other laboratory ﬁndings are nonspeciﬁc. Normocytic,
normochromic anemia may be present, but the white cell count
and platelet counts are usually normal. Increased hepatic
enzymes, such as alkaline phosphatase may also be seen. Sero-
logical tests, such as rheumatoid factor and antinuclear antibodies
are typically negative.2
8.1. Temporal artery biopsy
Clinicians vary in their views on the usefulness of a TAB in the
management of GCA. Some suggest it is of value in conﬁrming the
diagnosis particularly when patients require long-term immuno-
suppressive therapies; others feel that the high false-negative rate
diminishes the value of the procedure.35 As noted in Table 3, the
BSR/BHPR guidelines include a biopsy as an essential part of the
diagnosis and management pathway. One-third of the patients
with signs and symptoms of GCA may have a negative TAB, which
may be because of localized involvement of arteries in the head and
neck. The “skip” lesions are seen in about one-third of the biopsies;
some segments showing active disease are as short as 350 mm.36
Various factors can inﬂuence the biopsy result, such as size of the
biopsy, number of sections examined, and the duration of the
corticosteroid therapy before the biopsy. Biopsy is most useful if
performed within 24 hours of starting steroids. The changes of
arteritis can be seen several days after the initiation of corticosteroid
therapy.37 Therefore, one shouldnotdelay the treatment for the sake
Table 5
Differential diagnosis of PMR
Differential diagnosis of PMR
Soft tissue lesions Rotator cuff lesions, adhesive capsulitis
Joint disease Osteoarthritis, rheumatoid arthritis
Connective tissue diseases
Infections Localized and systemic
Muscle disease Myopathy, polymyositis
Bone disease Osteomalacia
Hypothyroidism
Parkinsonian syndromes
Neoplastic disease Multiple myeloma, lymphoma
Fibromyalgia and regional
pain syndromes
Functional
PMR¼ polymyalgia rheumatica.
Box 1. Steroid regime for polymyalgia rheumatica
 Start prednisolone 15e20 mg once daily for four weeks
and monitor clinical response.
 Reduce prednisolone by 2.5 mg every four weeks until
down to 10 mg daily.
 Further reduction by 1 mg every four weeks until down
to minimum maintenance dose of 5e7.5 mg daily.
 Continue maintenance dose for 6e12 months.
 Finally reduce by 1 mg every four weeks and stop.
 Some patients may require a much longer or even
lifelong treatment on a low dose.
M. Patel, D.R. Forsyth / Journal of Clinical Gerontology & Geriatrics 2 (2011) 7e1210of biopsy. A negative biopsy does not exclude GCA; however, it
remains the gold standard test for conﬁrming GCA and should be
considered in all case where possibility of GCA cannot be excluded
clinically.38
8.2. TAB-negative GCA
Those patients in whom the clinical presentation, including the
response to treatment is strongly suggestive of GCA despite the
negative biopsy are considered to have biopsy-negative GCA.39
8.3. Imaging in GCA
Ultrasound (US) examination of the temporal and occipital
arteries in patients with GCA can detect abnormalities, such as
reduced blood ﬂow, stenoses, occlusions, and a “halo” surrounding
the lumen of the vessel.40 Most of these changes are nonspeciﬁc;
however, the halo sign has been shown to have a speciﬁcity of 100%
in one study.41 There is no recognized role for joint US in diagnosis
of PMR, although US has been proposed as a way of conﬁrming
large joint (shoulder and hip) synovitis,42 as has shoulder magnetic
resonance imaging.43
Angiographic examination of the aortic arch and its branches
may show abnormalities among those with features of large artery
involvement.44 Magnetic resonance imaging and computerized
scanning can also detect large artery involvement; however, overall
vascular changes are not as clearly demonstrated as with angiog-
raphy. The BSR/BHPR guidelines recommend aortic imaging at time
of diagnosis of large vessel GCA and subsequent biannual chest
radiography to look for thoracic aortic arch widening.11
Positron emission tomography can detect the presence of
subclinical inﬂammationof the large vessels as shownbyhighuptake
of radiolabeled glucose analog in some cases of GCA and PMR.45
The use of imaging in the management of GCA has not yet
changed the clinical practice concerning the requirement of a TAB.
9. Pathology
Large- and medium-sized arteries are affected, the involvement
is patchy, and skip lesions are often found. There is preferential
involvement of muscular arteries with well-developed internal and
external elastic laminae. The histological appearance in GCA is
characteristic with panarteritis and giant cell granuloma formation,
often in close proximity to a disrupted internal elastic lamina. The
adventitia is usually invaded by mononuclear, and occasionally
polymorphonuclear, inﬂammatory cells.
There has been little to support a concept of primary muscle
disease in PMR. Serum aldolase and creatine phosphokinase are
normal, and there is no abnormality on electromyography. Muscle
biopsy has shown Type II atrophy alone and there is no evidence of
inﬂammatory changes.46
10. Differential diagnosis
The differential diagnosis in an older person with muscle pain,
stiffness, and an increased ESR is wide, as many other conditions
can present in a similar fashion (Table 5). It is important to rule out
any underlying infection, malignancy, or inﬂammatory arthritis.
The value of a careful history and examination in the assessment of
these patients cannot be overemphasized.
11. Management
Early diagnosis and treatment with corticosteroids is most
important in the treatment of GCA; they rapidly relieve thesymptoms and reduce the incidence of complications, such as
blindness. The response to corticosteroids is usually dramatic and
occurs within days. Corticosteroid treatment has improved the
quality of life for patients, although there is no evidence that
treatment reduces the duration of the disease. Initially, steroids
should be given in a dosage sufﬁcient to control the disease. In
practice, most studies report starting with 10e20 mg prednisolone
daily to treat PMR and 40e60 mg for GCA.47 Reducing the dose of
steroids too quickly may result in a ﬂare-up of symptoms. The aim
is to wean the patient off steroids or ﬁnd the minimum mainte-
nance dose required to relieve symptoms and suppress the ESR
(Boxes 1 and 2). The use of intravenous methylprednisolone at
a dose of 500 mge1 g daily for three days is recommended only for
complicated GCA (where there is evolving visual loss, history of
amaurosis fugax, or tongue claudication).48,49
Up to 50% of patients will be able to discontinue steroids after
two years and somemay take longer.50,51 Relapses aremost likely in
the ﬁrst 18months of treatment, but they can occur after apparently
successful treatment when corticosteroids have been discontinued.
At present, there is no way of predicting those patients most at risk.
Diagnosis of relapse should bemade on the basis of clinical features
because the ESR and C-reactive protein concentration are often not
increased during relapses or may be increased as a result of other
causes. However, where symptoms recur and the acute phase
proteins are normal, the possibility of other comorbid conditions
being responsible for the symptoms must be considered. The
biomarker procalcitonin has been favorably evaluated for use as
a tool to distinguish bacterial systemic sepsis from an autoimmune
diseaseﬂare52 but is yet to enterwidespread clinical practice outside
of the intensive care setting.
Patients who are unable to “wean-off” prednisolone because of
recurring symptoms, or who develop serious corticosteroid-related
side effects, pose particular problems. Various drugs, such as meth-
otrexate and azathioprine have been tried for their steroid sparing
effect; however, overall consensus is that, the beneﬁt is only
Box 2. Steroid regime for giant cell arteritis
 Start prednisolone 60 mg once daily for 6e8 weeks and
monitor clinical response.
 Reduce prednisolone by 5 mg every week until down to
20e30 mg.
 Reduction by 2.5 mg every two weeks until down to
10 mg once daily.
 Further reduction by 1 mg every four weeks until down
to minimum maintenance dose of 5e7.5 mg daily.
 Continue maintenance dose for 6e12 months.
 Finally reduce by 1 mg every four weeks and stop.
 Some patients may require a much longer or even
lifelong treatment on a low dose.
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to have the best evidence54 and is endorsed in the recent BSR/BHPR
guidelines particularly for use in GCA. Most of the published studies
have a relatively small number of patients, with a short duration of
follow-upandhighnumberswithdrawing fromtreatment. Anecdotal
studieswith inﬂiximabhave shown its effectiveness in reducingneed
for high dose steroids in otherwise treatment resistant cases of PMR;
however, number of patients in these was very small.55
Long-term use of oral corticosteroids is associated with loss of
bone mineral density and increased fracture risk, particularly in
sites rich in trabecular bone.56 Bone loss occurs early in the course
of treatment, although risk of fracture is roughly associated with
cumulative steroid dose. It has been estimated that 30%e50% of
long-term users of corticosteroids will experience a fracture,57,58
and the associated morbidity after such an event is substantial.59
Both GCA and PMR require long-term corticosteroid therapy and
these patients should be started on appropriate preventive therapy
for steroid-induced osteoporosis to avoid added morbidity and
mortality from fractures.60
There appears to be an increased incidence of cerebrovascular
events with GCA,61 especially in the vertebrobasilar territory.62
British guidelines now recommend using patient appropriate
antithrombotic therapy.11
Regular urinalysis for glycosuria and checks for hypertension
should also be performed while patients remain on steroids.
12. Overview of management of PMR and GCA
1. Consider GCA in all patients with PMR.
2. Prescribe steroids early to relieve symptoms and prevent
complications.
3. Ensure that patients with PMR or GCA seek urgent medical
attention if they develop new visual symptoms.
4. Monitor response to treatment clinically and with changes in
inﬂammatory markers.
5. Always consider other possible diagnosis if symptoms do not
improve with steroid treatment.
6. If symptoms worsen or reappear, increase the dosage of
steroids to the dose that previously controlled the symptoms.
References
1. Salvarani C, Cantini F, Boiardi L, Hunder GG. Polymyalgia rheumatica and giant
cell arteritis. N Engl J Med 2002;347:261e71.
2. Brooks RC, McGee SR. Diagnostic dilemmas in polymyalgia rheumatica. Arch
Intern Med 1997;157:162e8.
3. Kyle V, Tudor J, Wraight EP, Gresham GA, Hazleman BL. Rarity of synovitis in
polymyalgia rheumatica. Ann Rheum Dis 1990;49:155e7.
4. Aiello PD, Trautmann JC, McPhee TJ, Kunselman AR, Hunder GG. Visual prog-
nosis in giant cell arteritis. Ophthalmology 1993;100:550e5.5. Hayreh SS. Anterior ischaemic optic neuropathy. Differentiation of arteritis
from non arteritic type and its management. Eye (Lond) 1990;4:25e41.
6. Nuenninghoff DM, Hunder GG, Christianson TJ, McClelland RL, Matteson EL. Inci-
dence and predictors of large-artery complication (aortic aneurysm, aortic
dissection, and/or large-artery stenosis) inpatientswithgiant cell arteritis.Arthritis
Rheum 2003;48:3522e31.
7. Bird HA, Esselinckx W, Dixon AS, Mowat AG, Wood PH. An evaluation of criteria
for polymyalgia rheumatica. Ann Rheum Dis 1979;38:434e9.
8. Hunder C, Bloch D, Michel B, et al. The American College of Rheumatology 1990
criteria for the classiﬁcation of giant cell (temporal) arteritis. Arthritis Rheum
1990;33:1122e8.
9. Fitzcharles M, Esdaile JM. Atypical presentation of polymyalgia rheumatica.
Arthritis Rheum 1990;33:403e6.
10. Dasgupta B, Borg FA, Hassan N, Barraclough K, Bourke B, Fulcher J, et al. BSR
and BHPR guidelines for the management of polymyalgia rheumatica. Rheu-
matology (Oxford) 2010 Jan;49:186e90. Epub Nov 12, 2009.
11. Dasgupta B, Borg FA, Hassan N, Alexander L, Barraclough K, Bourke B, et al. BSR
and BHPR guidelines for the management of giant cell arteritis. Rheumatology
(Oxford) 2010;49:1594e7 [Epub ahead of print].
12. Ntatsaki E, Watts RA. Management of polymyalgia rheumatica. BMJ 2010 Feb
4;340:c620. doi:10.1136/bmj.c620.
13. Cantini F, Niccoli L, Storri L, et al. Are polymyalgia rheumatica and giant cell
arteritis the same disease? Semin Arthritis Rheum 2004;33:294e301.
14. Salvarani C, Gabriel S, O’Fallon W, Hunder GG. Epidemiology of polymyalgia
rheumatica in Olmsted County, Minnesota 1970-1991. Arthritis Rheum
1995;38:369e73.
15. Lawrence R, Helmick C, Arnett FC, Deyo RA, Felson DT, Giannini EH, et al.
Estimates of the prevalence of arteritis and selected musculoskeletal disorders
in the United States. Arthritis Rheum 1998;41:778e99.
16. González-Gay M, Garcia-Porrua C, Rivas M, Rodriguez-Ledo P, Llorca J. Epide-
miology of biopsy proven giant cell arteritis in northwestern Spain: trend over
an 18 year period. Ann Rheum Dis 2001;60:367e71.
17. Machedo E, Michet C, Ballard DJ, Hunder GG, Beard CM, Chu CP, et al. Trends in
incidence and clinical presentation of temporal arteritis in Olmsted county
Minnesota, 1950-1985. Arthritis Rheum 1988;31:745e9.
18. Li WL, Lo Y, Leung MH, Wong WS, Mok MY. The clinical course of polymyalgia
rheumatica in Chinese. Clin Rheumatol 2010;29:199e203.
19. Hu Z, Yang Q, Zeng S, Li J, Wu X, Cao L, et al. Giant cell arteritis in China:
a prospective investigation. Angiology 2002;53:457e63.
20. Chen CH, Kung SY, Tsai YY, Liao HT, Chou CT, Huang DF. Temporal arteritis.
J Chin Med Assoc 2005 Jul;68:333e5.
21. Kobayashi S, Yano T, Matsumoto Y, Numno F, Nakajima N, Yasuda K, et al.
Clinical and epidemiologic analysis of giant cell (temporal) arteritis from
a nationwide survey in 1998 in Japan: the ﬁrst government-supported
nationwide survey. Arthritis Rheum 2003;49:594e8.
22. Liu NH, LaBree LD, Feldon SE, Rao NA. The epidemiology of giant cell arteritis:
a 12-year retrospective study. Ophthalmology 2001;108:1145e9.
23. Lee JL, Naguwa SM, Cheema GS, Gershwin ME. The geo-epidemiology of
temporal (giant cell) arteritis. Clin Rev Allergy Immunol 2008 Oct;35:88e95.
24. Bacon P, Doherty S, Zuckerman A. Hepatitis B antibody in polymyalgia rheu-
matica. Lancet 1975;2:476e8.
25. Cimmino M, Grazi G, Balistreri M, Accardo S. Increased prevalence of antibodies
to adenovirus and respiratory syncytial virus in polymyalgia rheumatica. Clin
Exp Rheumatol 1993;11:309e13.
26. Helweg-Larsen J, Tarp B, Obel N, Baslund B. No evidence of parvovirus B19, Chla-
mydia pneumoniae or humanherpes virus infection in temporal artery biopsies in
patients with giant cell arteritis. Rheumatology (Oxford) 2002;41:445e9.
27. Cooper RJ, D’Arcy S, Kirby M, Al-Buhtori M, Rahman MJ, Proctor L, Bonshek RE.
Infection and temporal arteritis: a PCR-based study to detect pathogens in
temporal artery biopsy specimens. J Med Virol 2008;80:501e5.
28. Duhaut P, Bosshard S, Ducroix JP. Is giant cell arteritis an infectious disease? Bio-
logical and epidemiological evidence. Presse Med 2004 Nov 6;33(19 Pt 2):1403e8.
29. Elling P, Olsson AT, Elling H. Synchronous variations in the incidence of temporal
arteritis and polymyalgia rheumatica in Danish counties. Association with
epidemics of Mycoplasma pneumonia infection. Ugeskr Laeger 1997;159:4123e8.
30. Cid M, Campo E, Ercilla G, Palacın A, Vilaseca J, Villalta J, et al. Immunohisto-
chemical analysis of lymphoid and macrophage cell subsets and their immu-
nologic activation markers in temporal arteritis. Inﬂuence of corticosteroid
treatment. Arthritis Rheum 1989;32:884e93.
31. Smetana G, Shmerling R. Does this patient have temporal arteritis? JAMA
2002;287:92.
32. Kachroo A, Tello C, Bais R, Panush RS. Giant cell arteritis: diagnosis and
management. Bull Rheum Dis 1996;45:2e5.
33. Wise M, Agudelo G, Chimelewski W, McKnight K. Temporal arteritis with low
erythrocyte sedimentation rate. Arthritis Rheum 1991;34:1571e4.
34. Bengtsson B, Malmvall B. The epidemiology of giant cell arteritis including
temporalarteritis andpolymyalgia rheumatica.ArthritisRheum1981;24:899e904.
35. Hazleman B. Polymyalgia rheumatica and giant cell arteritis. In: Klippel JH,
Dieppe PA, editors. Rheumatology. 3rd ed. London: Mosby Elsevier Ltd; 2003. p.
1611e23.
36. Klein G, Campbell R, Hunder GG, Carney JA. Skip lesions in temporal arteritis.
Mayo Clin Proc 1976;51:504e8.
37. Achkar A, Lie J, Hunder G, O’Fallon WM, Gabriel SE. How does previous corti-
costeroid treatment affect the biopsy ﬁndings in giant cell arteritis? Ann Intern
Med 1994;120:987.
M. Patel, D.R. Forsyth / Journal of Clinical Gerontology & Geriatrics 2 (2011) 7e121238. Dahiya S, Gaffney K, Merry P, Scott D. Vasculitis: 368. Usefulness of temporal
artery biopsy in the diagnosis of giant cell arteritis. Rheumatology 2005;44
(Suppl. 1):i144. British Society for Rheumatology Annual Meeting April 19e22,
2005.
39. Liozon E, Jauberteau-Marchan M, Ly K, Loustaud-Ratti V, Soria P, Elisabeth
Vidal E. Giant cell arteritis with a low erythrocyte sedimentation rate:
comments on the article by Salvarani and Hunder. Arthritis Rheum
2002;47:692.
40. PfadenhauerK,WeberH.Duplexsonographyof the temporal andoccipital artery in
the diagnosis of temporal arteritis. A prospective study. J Rheumatol 2003;30:2177.
41. Schmidt W, Kraft H, Vorpahl K, et al. Colour duplex ultrasonography in the
diagnosis of temporal arteritis. N Engl J Med 1997;337:1336e42.
42. Scheel AK, Matteson EL, Dasgupta B, Bruyn GA, Ohrndorf S, Werner C, et al.
Reliability exercise for the polymyalgia rheumatica classiﬁcation criteria study:
the oranjewoud ultrasound substudy. Int J Rheumatol 2009;2009:738931.
43. Mori S, Koga Y, Ito K. Clinical characteristics of polymyalgia rheumatica in
Japanese patients: evidence of synovitis and extracapsular inﬂammatory
changes by fat suppression magnetic resonance imaging. Mod Rheumatol
2007;17:369e75. Epub Oct 19, 2007.
44. Evans J, Bowles C, Bjornsson J, Mullany CJ, Hunder GG. Thoracic aortic aneurysm
and rupture in giant cell arteritis: A descriptive study of 41 cases. Arthritis Rheum
1994;37:1539e47.
45. Blockmans D, Stroobants S, Maes A, Mortelmans L. Positron emission tomog-
raphy in giant cell arteritis and polymyalgia rheumatica: evidence for inﬂam-
mation of the aortic arch. Am J Med 2000;108:246e9.
46. Kojima S, Tajagi A, Ida M, Shiozawa R. Muscle pathology in polymyalgia
rheumatica: a histochemical and immunohistochemical study. Jpn J Med
1991;30:516e23.
47. Collier J. The management of polymyalgia rheumatica and giant cell arteritis.
Drug and Therap Bull 1993;31:65e8.
48. Chevalet P, Barrier J-H, Pottier P, Magadur-Joly G, Pottier MA, Hamidou M, et al.
A randomized multi-center controlled trial using intravenous pulses of
Methylprednisolone in the initial treatment of simple forms of giant cell
arteritis: a one year follow up study of 164 patients. J Rheumatol
2000;27:1484e91.
49. MazlumzadehM,HunderGG, Easley KA, Calamia CT,Matteson EL, GrifﬁngWL, et al.
Treatment of giant cell arteritis using induction therapy with high-dose glucocor-
ticoids. Arthritis Rheum 2006;54:3310e8.50. Chuang TY, Hunder GG, Ilstrup DM, Kurland LT. Polymyalgia rheumatica: a 10-
year epidemiological and clinical study. Ann Intern Med 1982;97:672e80.
51. Ayoub WT, Franklin CM, Toretti D. Polymyalgia rheumatica. Duration of
therapy and long-term outcome. Am J Med 1985;79:309e15.
52. Buhaescu I, Yood RA, Izzedine H. Serum procalcitonin in systemic autoimmune
diseasesdwhere are we now? Semin Arthritis Rheum 2010;40:176e83 [Epub
ahead of print].
53. Hoffman G, Cid M, Hellmann D, Guillevin L, Stone JH, Schousboe J, et al.
International Network for the Study of Systemic Vasculitides. A multicenter,
randomized, double blind, placebo-controlled trial of adjuvant methotrexate
treatment for giant cell arteritis. Arthritis Rheum 2002;46:1309e18.
54. Mahr AD, Jover JA, Spiera RF, Hernandez-Garcia C, Fernandez-Gutierrez B,
Lavalley MP, et al. Adjunctive methotrexate for treatment of giant cell arteritis:
an individual patient data meta-analysis. Arthritis Rheum 2007;56:2789e97.
55. Salvarani C, Cantini F, Niccoli L, Catanoso MG, Macchioni P, Pulsatelli L, et al.
Treatment of refractory polymyalgia rheumatica with inﬂiximab: A pilot study.
J Rheumatol 2003;30:760e3.
56. Adinoff A, Hollister J. Steroid-induced fractures and bone loss in patients with
asthma. N Engl J Med 1983;309:265e8.
57. Lukert B, Raisz L. Glucocorticoid-induced osteoporosis: Pathogenesis and
management. Ann Intern Med 1990;112:352e64.
58. Reid I,GreyA.Corticosteroidosteoporosis.BaillieresClinRheumatol1993;7:573e87.
59. Center J, Nguyen T, Schneider D, Sambrook P, Elsman J. Mortality after all major
types of osteoporotic fracture in men and women: an observational study.
Lancet 1999;353:878e82.
60. The Royal College of Physicians, The Bone and Tooth Society of Great Britain,
and The National Osteoporosis Society. Glucocorticoid induced osteoporosis:
guidelines for prevention and treatment. Prepared by a working group in
collaboration with: The Royal College of Physicians, The Bone and Tooth
Society of Great Britain, and The National Osteoporosis Society. London, UK:
Royal College of Physicians; 2002.
61. Pego-Reigosa R, Garcia-Porrua C, Piñeiro A, Dierssen T, Llorca J, Gonzalez-
Gay MA. Predictors of cerebrovascular accidents in giant cell arteritis in
a deﬁned population. Clin Exp Rheumatol 2004;22(6 Suppl. 36):S13e7.
62. Gonzalez-Gay MA, Vazquez-Rodriguez TR, Gomez-Acebo I, Pego-Reigosa R,
Lopez-Diaz MJ, Vazquez-Triñanes MC, et al. Strokes at time of disease diagnosis
in a series of 287 patients with biopsy-proven giant cell arteritis. Medicine
(Baltimore) 2009;88:227e35.
